Efficacy of Cytoflavin in patients with multiple sclerosis and fatigue
O. A. Mialovitska · 2015 · Ukrainian Medical Journal. Published 18 March 2015
What does this source report?
The Cytoflavin group’s MFIS score fell from 45.1±4.5 to 29±4.2 (reported within-group p<0.05). The comparator regimen included pentoxifylline, piracetam, meldonium and B vitamins. The result cannot be attributed to either piracetam or meldonium.
- Population and setting
- 62 screened; 53 with fatigue allocated to Cytoflavin (20) or conventional therapy (33)
- Evidence type
- Human comparative study
- Preparation
- See the original report; formulation details require verification.
- Source language
- Ukrainian
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Unequal groups; randomization and blinding are not established.
- 62 is the screened population, not the number allocated to treatment groups.
- A within-group change is not a demonstrated between-group effect; fatigue improvement is not disease modification.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Publisher full text
Review depth: Methods and results reviewed
Source access and review scope
Source text reviewed at the access level stated; no independent verification of patient data.
Recorded source-check date: 2026-10-03. This date does not imply a completed systematic review.
Cite and trace this record
Original source: O. A. Mialovitska. Efficacy of Cytoflavin in patients with multiple sclerosis and fatigue Ukrainian Medical Journal. Published 18 March 2015 2015.
Molekul research summary: https://molekul.io/research/ms-fatigue-cytoflavin-2015. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry